Vernakalant Versus Flecainide: Atrial Contractility
Atrial Fibrillation
About this trial
This is an interventional diagnostic trial for Atrial Fibrillation focused on measuring Atrial fibrillation, Vernakalant, Flecainide, Echocardiography
Eligibility Criteria
Inclusion Criteria:
- persistent AF or paroxysmal AF
- eligible for treatment with vernakalant or flecainide infusion to restore sinus rhythm
- receiving adequate anticoagulant therapy (or having an episode of AF lasting < 24 hours)
Exclusion Criteria:
- refusal or inability to give informed consent to participate in this study
- atrial flutter
- contra-indications for receiving vernakalant or flecainide according to MUMC+ protocol (unstable hemodynamic condition, LVEF < 40%, inadequate potassium levels, acute ischaemia, sinus node dysfunction)
- age < 18 years
Sites / Locations
- Maastricht University Hospital
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Flecainide
Vernakalant
Patients randomized to flecainide will receive a 10-minute infusion of 2 mg/kg (maximal 150 mg) flecainide. If the patient is still in AF 1 hour after the infusion, electrical cardioversion will be performed according to protocol.
Patients randomized to vernakalant will receive a 10-minute infusion of 3 mg/kg vernakalant, followed by a 15 minute observation period. If the patient is still in atrial fibrillation, an additional 10-minute infusion of 2 mg/kg vernakalant will be given. If the patient is still in AF 1 hour after the infusion, electrical cardioversion will be performed according to protocol.